TABLE 1.
Description of AH Cohorts
| BIDMC AH registry (n = 39) | ELAD (n = 91) | InTEAM (n = 20) | TREAT | ||
|---|---|---|---|---|---|
| Heavy Drinker (n = 169) | AH (n = 196) | ||||
| Study description | A prospective single‐center observational study of AH; subjects were consecutively recruited from the hospitalized patients at BIDMC | A phase 3, randomized, open‐label, multicenter clinical trial of ELAD (VTL‐308); subjects with baseline samples were included in this study | A multicenter prospective observational study aimed to identify molecular targets in AH; subjects with liver biopsy were included in this study | A multicenter observational case‐control study comparing subjects with heavy drinking and AH | |
| Age | <35: 14 (36%) | <35: 31 (34%) | <35: 2 (10%) | <35: 44 (26%) | <35: 39 (20%) |
| ≥35: 25 (64%) | ≥35: 60 (66%) | ≥35: 18 (90%) | ≥35: 125 (74%) | ≥35: 157 (80%) | |
| Gender (% F) | 36% | 39% | 45% | 35% | 20% |
| Meeting AGA laboratory criteria for AH trials (%)a | 82.1% | 79.1% | 90.0% | — | 80.1% |
| MELD (median, IQR) | 28 (24, 34) | 27 (24, 30) | 21 (19, 26) | 7 (6, 8) | 23 (18, 27) |
| DF (median, IQR) | 58 (42, 97) | 47 (30, 67) | 19 (13, 36) | 0.5 (0.3, 1) | 41 (19, 61) |
| Total bilirubin (mg/dL, mean ± SD) | 18.7 ± 11.5 | 23.7 ± 8.7 | 13.1 ± 7.7 | 0.6 ± 0.6 | 14.2 ± 11.0 |
| Triglyceride (mg/dL, mean ± SD) | 101 ± 65 | 100 ± 54 | 137 ± 88 | 175 ± 122 | 127 ± 78 |
| LP‐Z (nmol/L) (mean ± SD) | 1440 ± 996 | 1295 ± 943 | 1680 ± 1256 | 76 ± 317 | 1611 ± 1296 |
| Z‐index (mean ± SD) | 0.63 ± 0.30 | 0.58 ± 0.25 | 0.63 ± 0.32 | 0.04 ± 0.11 | 0.56 ± 0.32 |
Abbreviations: F, female; and IQR, interquartile range.